EGFR and neoplasm: Indeed, we show that patients with EGFR mutated and miR-200 sign-down tumors are at higher risk of relapse independently of tumor stage, and, at the opposite, that patients with EGFR mutated and miR-200 sign-up tumors do not relapse and might not need adjuvant treatment.